BenevolentAI
built with scientists for scientists biological question how benevolent is drug discovery knowledge target cation precision medicine molecular design high con hypothesis driven drug discovery the benevolent is a validated computational platform that supports end to end enabled drug discovery and development built with scientists for scientists introspection tools enable real time in silico experimentation can we treat by reversing insulin resistance in by reducing oxidative stress empowers scientists to decipher complex disease biology discover novel targets run in silico experiments in real time accelerate the development of drug candidates make high con decisions increase the probability of discovering a successful drug scientists iteratively queries for execution by our models | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
12 of 42
Related slides by other companies
Exscientia
Investor Presentation
May 2023
the drug discovery process today | Exscientia
Absci
Investor Presentation
April 2023
an emerging innovative approach is uniquely positioned in the emerging field of drug discovery | Absci
MaxCyte
Investor Presentation
January 2024
business model drug discovery market | MaxCyte
Absci
Investor Presentation
October 2023
the leading full stack platform for drug creation sos | Absci
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io